Article thumbnail
Location of Repository

The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin

By C. Pardieu, R. Vigan, S.J. Wilson, A. Calvi, T. Zang, P. Bieniasz, P. Kellam, G.J. Towers, S.J.D. Neil and J.U. Jung


Tetherin (CD317/BST2) is an interferon-induced membrane protein that inhibits the release of diverse enveloped viral particles. Several mammalian viruses have evolved countermeasures that inactivate tetherin, with the prototype being the HIV-1 Vpu protein. Here we show that the human herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV) is sensitive to tetherin restriction and its activity is counteracted by the KSHV encoded RING-CH E3 ubiquitin ligase K5. Tetherin expression in KSHV-infected cells inhibits viral particle release, as does depletion of K5 protein using RNA interference. K5 induces a species-specific downregulation of human tetherin from the cell surface followed by its endosomal degradation. We show that K5 targets a single lysine (K18) in the cytoplasmic tail of tetherin for ubiquitination, leading to relocalization of tetherin to CD63-positive endosomal compartments. Tetherin degradation is dependent on ESCRT-mediated endosomal sorting, but does not require a tyrosine-based sorting signal in the tetherin cytoplasmic tail. Importantly, we also show that the ability of K5 to substitute for Vpu in HIV-1 release is entirely dependent on K18 and the RING-CH domain of K5. By contrast, while Vpu induces ubiquitination of tetherin cytoplasmic tail lysine residues, mutation of these positions has no effect on its antagonism of tetherin function, and residual tetherin is associated with the trans-Golgi network (TGN) in Vpu-expressing cells. Taken together our results demonstrate that K5 is a mechanistically distinct viral countermeasure to tetherin-mediated restriction, and that herpesvirus particle release is sensitive to this mode of antiviral inhibition

Year: 2010
OAI identifier:
Provided by: UCL Discovery

Suggested articles


  1. (2001). A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation.
  2. (2007). An interferon-alphainduced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.
  3. (2009). Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.
  4. (2006). Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation.
  5. (2009). Broadspectrum inhibition of retroviral and filoviral particle release by tetherin.
  6. (2003). Bst-2/ HM1.24 is a raft-associated apical membrane protein with an unusual topology.
  7. (2007). Clathrinmediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif.
  8. (2008). Cytomegalovirus immune evasion.
  9. (2005). Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.
  10. (2005). Downregulation of cell surface receptors by the K3 family of viral and cellular ubiquitin E3 ligases.
  11. (2007). Downregulation of gamma interferon receptor 1 by Kaposi’s sarcoma-associated herpesvirus K3 and K5.
  12. (2000). Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins.
  13. (2008). Downregulation of NKG2D and NKp80 ligands by Kaposi’s sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.
  14. (2008). ESCRT complexes and the biogenesis of multivesicular bodies.
  15. (2005). HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway.
  16. (2009). Herpes simplex virus type 1 production requires a functional ESCRT-III complex but is independent of TSG101 and ALIX expression.
  17. (2006). Herpesvirus assembly: a tale of two membranes.
  18. (2008). HIV-1 accessory proteins–ensuring viral survival in a hostile environment.
  19. (2009). HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.
  20. (2009). HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5:
  21. (2006). HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2:
  22. (2008). Host restriction factors blocking retroviral replication.
  23. (2009). Human immunodeficiency virus, restriction factors, and interferon.
  24. (2000). Identification and analysis of the K5 gene of Kaposi’s sarcoma-associated herpesvirus.
  25. (2009). Inhibition of Lassa and Marburg virus production by tetherin.
  26. (2000). Inhibition of MHC class I-restricted antigen presentation by gamma 2-herpesviruses. Proc Natl Acad Sci
  27. (2008). Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
  28. (2006). Kaposi sarcoma herpesvirus K5 removes CD31/PECAM from endothelial cells.
  29. (2003). Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile.
  30. (2006). Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules.
  31. (2009). Membrane scission by the ESCRT-III complex.
  32. (2009). Modulation of the immune system by Kaposi’s sarcoma-associated herpesvirus.
  33. (1999). Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.
  34. (2009). Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi’s sarcoma-associated herpesvirus.
  35. (2009). Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 5:
  36. (2009). Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists. Cell Host Microbe.
  37. (1999). One step screening of retroviral producer clones by real time quantitative PCR.
  38. (2009). Protein kinase R reveals an evolutionary model for defeating viral mimicry.
  39. (2006). Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2:
  40. (2001). Quantitative, fluorogenic probe PCR assay for detection of human herpesvirus 8 DNA in clinical specimens.
  41. (2009). Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317by intracellular sequestration.Proc NatlAcad SciUSA.
  42. (2009). Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5: e1000300. doi:10.1371/ journal.ppat.1000300.
  43. (2009). Tetherin inhibits HIV-1 release by directly tethering virions to cells.
  44. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
  45. (2009). Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.
  46. (2009). The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 5:
  47. (2006). The interferon response circuit: induction and suppression by pathogenic viruses.
  48. (2008). The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
  49. (2002). Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation.
  50. (2004). Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression.
  51. (2008). Vaccinia virus morphogenesis and dissemination.
  52. (2009). Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
  53. (2009). Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
  54. (2009). Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.
  55. (2007). X box binding protein XBP-1s transactivates the Kaposi’s sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.